The Role of Postoperative Antibiotics in Laparoscopic Cholecystectomy
Launched by MINIA UNIVERSITY HOSPITAL · Sep 19, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the use of antibiotics after laparoscopic cholecystectomy, which is a surgery to remove the gallbladder. Specifically, researchers want to compare two types of antibiotics given after the surgery: one delivered through an IV (parenteral) and one taken by mouth (oral). The goal is to see which method is better at preventing infections that can happen after the surgery.
To participate in this trial, you need to be an adult over 18 years old who is scheduled for laparoscopic cholecystectomy. However, individuals with certain health conditions, like diabetes or cancer, or those who have had recent antibiotics, won't be eligible. If you choose to join, you will help researchers learn more about preventing infections after surgery, which could lead to better care for future patients. The trial is currently recruiting participants, and all genders are welcome to take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (aged above 18 years) undergoing laparoscopic cholecystectomy.
- Exclusion Criteria:
- • patients with comorbidities (Diabetes, malignancies, Immunosuppressed). Lost of follow-up. Patients received antibiotics within 72 hr before admission. Complicated cases involved, gangrenous and perforated cholecystitis and abscess.
About Minia University Hospital
Minia University Hospital is a leading healthcare institution dedicated to advancing medical research and enhancing patient care through innovative clinical trials. As a prominent sponsor, the hospital is committed to conducting high-quality, ethical research that adheres to rigorous scientific standards and regulatory guidelines. With a multidisciplinary team of experienced researchers and healthcare professionals, Minia University Hospital focuses on a wide range of therapeutic areas, aiming to improve treatment outcomes and contribute to the global body of medical knowledge. Through collaboration with academic and industry partners, the hospital strives to facilitate the development of novel therapies and improve healthcare solutions for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minya, , Egypt
Patients applied
Trial Officials
Asmaa A Elsayed, Ph.D.
Principal Investigator
Sohag University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported